ArticleFrontiers in pediatrics2026
Co-segregation of
Article in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Vasovagal syncope (VVS) is the most prevalent subtype of reflex syncope. However, the genetic etiology underlying familial recurrent VVS has not been fully elucidated. Methods: We recruited a multigenerational Chinese pedigree with three-generation recurrent early-onset VVS. Whole-exome sequencing was performed to screen pathogenic variants. Variant interpretation was conducted following the ACMG-AMP 2015 criteria, and multiple in-silico prediction tools were applied to evaluate variant pathogenicity. Clinical laboratory indicators of affected family members were collected and analyzed. Results: The heterozygous WFS1 c.1480G>A (p.Gly494Ser) variant was identified and found to co-segregate with the syncope phenotype within this family. This variant is rare in public population databases and predicted to be potentially damaging to wolframin protein structure. It was classified as a Variant of Uncertain Significance (VUS) with moderate-strength evidence of PM2 and PP3. Concurrent hyperinsulinemia was detected in affected individuals, which may be confounded by obesity-related insulin resistance. Discussion: Our results hypothesize that WFS1 p.Gly494Ser may serve as a candidate susceptibility variant for VVS. This finding broadens the phenotypic spectrum of heterozygous WFS1 variants and provides preliminary evidence linking endoplasmic-reticulum-related and autonomic regulatory pathways to VVS predisposition. Further validation using large independent cohorts and comprehensive cellular functional experiments is required to confirm the causal role of this variant in VVS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.